Teratoma
16
2
3
10
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 15/100
0.0%
0 terminated out of 16 trials
100.0%
+13.5% vs benchmark
13%
2 trials in Phase 3/4
70%
7 of 10 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 10 completed trials
Clinical Trials (16)
Molecular Epidemiology of Pediatric Germ Cell Tumors
Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors
Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors
Establishing Prospective Mediastinal Tumor Database of PUMCH
Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors
Computer Aided Diagnostic Tool on Computed Tomography Images for Diagnosis of Retroperitoneal Tumor in Children
A Randomized, Blinded, Placebo-controlled, Phase II Trial of LEE011 in Patients With Relapsed, Refractory, Incurable Teratoma With Recent Progression
Combination Chemotherapy and Pegfilgrastim in Treating Patients With Previously Untreated Germ Cell Tumors
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Germ Cell Cancer
Paclitaxel, Ifosfamide, and Carboplatin Followed By Autologous Stem Cell Transplant in Treating Patients With Germ Cell Tumors That Did Not Respond to Cisplatin
Sunitinib in Treating Patients With Metastatic Germ Cell Tumors That Have Relapsed or Not Responded to Treatment
Combination Chemotherapy in Treating Male Patients With Germ Cell Tumors
Combination Chemotherapy and Pegfilgrastim in Treating Men With Metastatic Germ Cell Tumors
Combination Chemotherapy in Treating Men With Germ Cell Cancer
Anterior Mediastinum Teratoma: A Case Report
11C-Acetate PET/CT Non-FDG-Avid Tumors